KMT2Ar clinical trials at UCSF
1 research study open to eligible people
KMT2Ar is a KMT2A gene rearrangement found in some leukemias, including AML. UCSF is studying ziftomenib with other drugs in people whose AML returned after treatment. The research tracks safety, tolerability, and antileukemic response.
Showing trials for
Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
open to eligible people ages 18 years and up
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
San Francisco, California and other locations
Last updated: